Posts

Posted on

BioSig Enters the New York Market with Its Signal Processing Technology for Electrophysiology

The Company installs its novel medical technology platform for arrhythmia care in a leading Center of Excellence

Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its technology in a leading New York City hospital.

The PURE EP(tm) is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. To date, more than 50 physicians have completed over 1,000 patient cases with the PURE EP(tm) System across twelve clinical sites.

The Northeast is one of the three strategic areas that the Company is focused on in the targeted commercial launch phase. BioSig’s PURE EP(tm) technology was installed at New York Presbyterian / Weill Cornell Medical Center in New York, NY, one of the nation’s most comprehensive, integrated healthcare systems and New York’s top-ranked hospital for 20 years1. Weill Cornell Medical Center which has commenced conducting patient cases with the PURE EP(tm) System in June 2021, offers one of the most extensive electrophysiology programs in the country.

“We are pleased to commence patient cases at one of the best-ranked centers for cardiology in our country and a leading institution in the New York City area. Our clinical strategy focuses on engaging medical centers of excellence that are recognized for their commitment to patient care and their support of clinical innovation and research, and we look forward to advancing our efforts with the Weill Cornell physician team,” commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.

The PURE EP(tm) System has been awarded FDA 510(k) clearance. The Company commenced a targeted commercial launch in 2020 and completed commercial sales to St. David’s HealthCare of Austin, Texas, an HCA Healthcare-owned hospital, and Mayo Foundation for Medical Education and Research that acquired multiple PURE EP(tm) units for clinical use across their Minnesota, Florida and Arizona campuses.

One in 18 Americans suffers from cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S. The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 20502. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the U.S. each year, resulting in approximately $6 billion in healthcare spending annually3.

About BioSig Technologies

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

1 New York-Presbyterian website: www.nyp.org

2 Top 10 Things You should Know About Heart Rhythm; Scripps Health.

3 Managing Atrial Fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Issue 4



Andrew Ballou
BioSig Technologies, Inc. 
Vice President, Investor Relations 
54 Wilton Road, 2nd floor
Westport, CT 06880
[email protected]
203-409-5444, x133

Posted on

Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021


Presentation to highlight Company’s current clinical stud


y


of lead compound LB-100 for Small Cell Lung Cancer

ALTADENA, CA, July 07, 2021 (GLOBE NEWSWIRE) — Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte” or the “Company”), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the MoneyShow July Virtual Expo taking place July 13-15, 2021. Registration is free and open to the public.

Event and Registration: MoneyShow July Virtual Expo
Presentation Date: Wednesday, July 14, 2021
Presentation Time: 3:20 p.m. ET

Lixte Founder and CEO John S. Kovach, M.D. will deliver a company overview, featuring the Company’s ongoing Phase 1b/2 clinical trial with City of Hope, a world-renowned independent cancer research and treatment center, to assess LB-100 for treatment of extensive stage-disease small cell lung cancer.

About Lixte Biotechnology Holdings, Inc.


Lixte Biotechnology Holdings, Inc.
 (Nasdaq:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the “on” switches because the “off” switches, especially the master “off” switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. Additional information can be obtained at the company’s website: www.lixte.com

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company’s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as “intend,” anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect” or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company’s filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

Lixte Contact:

[email protected]

General Phone: (631) 830-7092
Investor Phone: (888) 289-5533



Posted on

Thinking about trading options or stock in Sunnova Energy, Virgin Galactic, Generac, Nio, or Amazon.com?

PR Newswire

NEW YORK, July 7, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for NOVA, SPCE, GNRC, NIO, and AMZN.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-sunnova-energy-virgin-galactic-generac-nio-or-amazoncom-301326969.html

SOURCE InvestorsObserver

Posted on

Thinking about buying stock in Opiant Pharmaceuticals, RealNetworks, Vaxart, Clover Health, or Viewray?

PR Newswire

NEW YORK, July 7, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for OPNT, RNWK, VXRT, CLOV, and VRAY.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-opiant-pharmaceuticals-realnetworks-vaxart-clover-health-or-viewray-301326967.html

SOURCE InvestorsObserver

Posted on

Thinking about trading options or stock in BigCommerce, Apple, JinkoSolar, Tesla, or Shopify?

PR Newswire

NEW YORK, July 7, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for BIGC, AAPL, JKS, TSLA, and SHOP.

Click a link below then choose between in-depth options trade idea report or a stock score report.

Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each option trade idea for each stock.

Stock Report – Measures a stock’s suitability for investment with a proprietary scoring system combining short and long-term technical factors with Wall Street’s opinion including a 12-month price forecast.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-bigcommerce-apple-jinkosolar-tesla-or-shopify-301326977.html

SOURCE InvestorsObserver

Posted on

Smith Capital Investors Funds Celebrate 3 Years with Top-Decile Performance and Fee Reduction

Funds deliver risk-adjusted solid returns while cutting fees by three basis points (bps)

PR Newswire

WINDSOR, Conn. and DENVER, July 7, 2021 /PRNewswire/ — SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that the ALPS | Smith Total Return Bond Fund (SMTHX) and ALPS | Short Duration Bond Fund (SMDSX) have reached their three-year anniversaries.

Since launching three years ago, SMTHX and SMDSX have collectively grown to over $2.2 billion in net assets, ranking in the top decile for annualized returns since inception (6th and 10th percentile, respectively). For risk-adjusted returns (Sharpe Ratio), SMTHX ranks in the 4th percentile and SMDSX in the 3rd percentile.

Smith Capital Investors believes the strong performance was aided by the Funds’ active management approach and dynamic portfolio positioning capability—defensive, neutral, or opportunistic—which allowed allocation flexibility in response to varied market conditions.*

“The SS&C ALPS | Smith Capital Investors partnership has a strong track record, with outperformance and asset growth in a complex fixed income environment,” said Laton Spahr*, Portfolio Manager and President of SS&C ALPS Advisors. “We are committed to delivering funds that can improve investment outcomes. Both of these funds offer actively-managed, dynamic approaches aiming to provide strong risk-adjusted returns to investors.”

One of the founding principles of Smith Capital Investors is providing positive client experiences through investment performance and personal attention to client relationships and dialogue. In response, the fee was lowered on the ALPS | Smith Total Return Bond Fund by three bps, effective June 29, 2021. This reduction positions the Fund’s “I” share below the median for its category.

“We are incredibly proud of the results we’ve delivered in some of the most challenging markets on record. That said, our focus on investing excellence expands well beyond the competitive results we’ve produced for our investors; it’s about consistency,” said Gibson Smith*, Founder and Chief Investment Officer of Smith Capital Investors. “Few find fixed income exciting or inspiring, but for this team, it is our calling and our mission.”

Fund Objectives

The ALPS | Smith Total Return Bond Fund: The Fund seeks to obtain a total maximum return, consistent with the preservation of capital. Standardized Performance >>

The ALPS | Smith Short Duration Bond Fund: The Fund seeks as high a level of current income as is consistent with preservation of capital. Standardized Performance >>

For more information, please visit www.alpsfunds.com. 



*Performance data quoted represent past performance. Past performance is no guarantee of future results so that shares, when redeemed, may be worth more or less than their original cost. The investment return and principal value will fluctuate. Current performance may be higher or lower than the performance quoted. For the most current month-end performance data please call 866.759.5679. Performance includes reinvested distributions and capital gains

Important Disclosures and Definitions


An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1.866.759.5679 or visit www.alpsfunds.com. Please read the prospectus carefully before investing.

An investment in the Funds involves risk, including loss of principle.

Fixed Income Securities Risk. A rise in interest rates typically causes bond prices to fall. The longer the duration of the bonds held by a fund, the more sensitive it will likely be to interest rate fluctuations. Duration measures the weighted average term to maturity of a bond’s expected cash flows. Duration also represents the approximate percentage change that the price of a bond would experience for a 1% change in yield. For example: the price of a bond with a duration of 5 years would change approximately 5% for a 1% change in yield. The price of a bond with a duration of 10 years would be expected to decline by approximately 10% if its yield was to rise by +1%. Bond yields tend to fluctuate in response to changes in market levels of interest rates. Generally, if interest rates rise, a bond’s yield will also rise in response; the duration of the bond will determine how much the price of the bond will change in response to the change in yield.

The Fund’s investments in fixed-income securities and positions in fixed-income derivatives may decline in value because of changes in interest rates. As nominal interest rates rise, the value of fixed-income securities and any long positions in fixed-income derivatives held by the Fund are likely to decrease, whereas the value of its short positions in fixed-income derivatives is likely to increase.

Market Risk. Overall securities market risks may affect the value of individual instruments in which the Fund invests. Factors such as domestic and foreign economic growth and market conditions, interest rate levels, and political events affect the securities and derivatives markets. When the value of the Fund’s investments goes down, your investment in the Fund decreases in value and you could lose money.

basis points (bps):
A unit that is equal to 1/100th of 1% and is used to denote the change in a financial instrument.
 

*Laton Spahr and Gibson Smith are Registered Representatives of ALPS Distributors, Inc.

ALPS Portfolio Solutions Distributor, Inc. is the distributor for the Funds.

ALPS Distributors, Inc., ALPS Advisors, Inc. and ALPS Portfolio Solutions Distributor, Inc. are affiliated.

About SS&C Technologies
SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. Some 18,000 financial services and healthcare organizations, from the world’s largest companies to small and mid-market firms, rely on SS&C for expertise, scale, and technology. Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.

About SS&C ALPS Advisors
SS&C ALPS Advisors, Inc., a wholly-owned subsidiary of SS&C Technologies, Inc., is a leading provider of investment products for advisors and institutions. Headquartered in Denver, CO with $18.5 billion under management as of June 30, 2021, ALPS Advisors is an open architecture boutique investment manager offering portfolio building blocks, active insight, and an unwavering drive to guide clients to investment outcomes across sustainable income, thematic and alternative growth strategies. For more information, visit www.alpsfunds.com.

About Smith Capital Investors
Smith Capital Investors LLC, a Colorado-based investment management firm, is focused on income investing with a keen eye on risk-adjusted returns and preservation of capital. Smith Capital Investors deploys an actively managed, fundamentally driven investment process led by an experienced, investment-centric, and proven team of investment professionals. For more information on Smith Capital Investors, please visit www.smithcapitalinvestors.com.  

 

Cision View original content:https://www.prnewswire.com/news-releases/smith-capital-investors-funds-celebrate-3-years-with-top-decile-performance-and-fee-reduction-301326961.html

SOURCE SS&C ALPS Advisors

Posted on

Hinge Promotes Michelle Parsons to Chief Product Officer

Michelle will lead product innovation aimed at making Hinge the best dating experience for all singles.

PR Newswire

NEW YORK, July 7, 2021 /PRNewswire/ — Hinge, the dating app “designed to be deleted,” has announced the promotion of Michelle Parsons to Chief Product Officer. As Chief Product Officer, Michelle will focus on both enhancing the user experience through product innovations and developing internal systems that will help scale product development. Tim MacGougan, Hinge’s current CPO, is stepping into the newly-created Chief Design Officer role as the company doubles down on its goal to have the most effective app design.

Prior to Hinge, Michelle had extensive product leadership experience at Spotify as the Product Lead of Personalization and at Netflix as the Product Lead of Global Kids and Family. She is deeply skilled and passionate about articulating a brand’s vision and delivering clear workstreams that support employee and company growth. Since joining the company in January 2021, Michelle has made significant progress implementing Hinge’s strategic vision of getting users off the app and into meaningful relationships through end-to-end product discovery, development and growth.

Having met her partner of five years on Hinge, Michelle leverages her personal experience using the app to bring a unique perspective to product development. As a part of the LGBTQIA+ community, Michelle understands the challenge of finding a space that feels welcoming and is committed to creating an inclusive app experience for all. Most recently, Michelle has supported the integration of in-app features on Hinge — including choice of pronouns and sexual orientation descriptors — to do just that.

“As someone who found love on Hinge, I know the profound impact of what we do every day. I’m passionate about continuing to innovate across the platform to create the most impactful and supportive experience for our users,” Michelle said. “At Hinge, our product team has a huge opportunity to drive fresh innovation, not only within our app experience, but also to lead the industry as a whole. I’m excited for the product updates and innovations we’ll be sharing in the coming months.”

In the near term, Michelle and her team are prioritizing four primary product areas: self-expression, interaction, inclusion and user discovery. Hinge’s current in-depth profiles allow users to showcase their personalities, and future in-app features will empower daters to share a 3D version of themselves, including rich media within profiles and conversations.

“To help every Hinge user find love, we need to continue to lead our industry in product innovation and design. Given Michelle’s previous work in personalizing products at Netflix and Spotify, she is the perfect person to help make Hinge a more individualized and inclusive app for all daters,” said Justin McLeod, Founder and CEO of Hinge. “We’re thrilled to elevate her to this new role.”

About Hinge
Hinge is the dating app for people who want to get off dating apps. In today’s digital world, singles are so busy matching that they’re not actually connecting, which is what matters most. Hinge is on a mission to change that. So we built an app that’s designed to be deleted. On Hinge, there are no rules, timers, or games. Instead, you’ll have unique conversations over what you’ve shared on your detailed profile. We’re for people who want to get off the app and out on great dates. And it’s resonating. For two years running, Hinge has been the fastest-growing dating app in the United States, United Kingdom, Canada, and Australia. Hinge was acquired by Match Group (NASDAQ:MTCH) in 2018.

Contact:
 [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hinge-promotes-michelle-parsons-to-chief-product-officer-301326319.html

SOURCE Hinge

Posted on

Inpixon Continues Contract Win Momentum With Multi-Year Smart Office App Agreement With Global Social Media Company to Facilitate Office Reopenings

All-in-One App Solves Hybrid Workforce Challenges by Integrating Numerous Workplace Services and Tools into a Unified Employee Experience Solution With Desk Booking, Communications, Meetings, Safety and More

PR Newswire

PALO ALTO, Calif., July 7, 2021 /PRNewswire/ — Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced that its smart office app, which was added to the Company’s product portfolio with the recent acquisition of The CXApp, has been selected by a leading global social media and information sharing company with hundreds of millions of active users worldwide for implementation across dozens of corporate locations. Among other features, the location-aware app allows employees to reserve workspace across thousands of desks, a key capability in enabling the post-pandemic, agile workplace.

Inpixon’s smart office app, a purpose-built mobile gateway to the new digital workplace, connects remote, in-office, and in-transit employees while promoting productivity and engagement by providing nearly all of a company’s employee-facing information and resources in one place. Through a custom-branded, employee-personalized experience, the app unifies numerous workforce capabilities including desk and conference room booking, an employee directory, company notifications, visitor management, virtual meetings, space utilization analytics, single sign-on, health screenings, surveys, and polls. The comprehensive app will utilize Inpixon Maps and Inpixon On-Device Positioning leveraging Bluetooth low-energy (BLE) beacons.

“To empower their distributed workforces, many organizations are looking to provide a centralized hub for unified employee experiences to bring connection points to employees and that provide them the ability to manage different types of office scenarios from their personal devices,” commented Nadir Ali, CEO of Inpixon. “Our awarding winning smart office app provides essential tools that assist with workplace re-entry including features such as blue-dot navigation and automated check-in and check-out for desk and room bookings. We are proud to win this contract, and we believe it exemplifies the rapid adoption of our smart office app by major global organizations. We expect this positive momentum to continue.”

About Inpixon

Inpixon® (Nasdaq: INPX) is the innovator of Indoor Intelligence™, delivering actionable insights for people, places and things. Combining the power of mapping, positioning and analytics, Inpixon helps to create smarter, safer, and more secure environments. The company’s Indoor Intelligence and mobile app solutions are leveraged by a multitude of industries to optimize operations, increase productivity, and enhance safety. Inpixon customers can take advantage of industry leading location awareness, RTLS, workplace and hybrid event solutions, analytics, sensor fusion and the IoT to create exceptional experiences and to do good with indoor data. For the latest insights, follow Inpixon on LinkedIn, and Twitter, and visit inpixon.com.

Safe Harbor Statement

All statements in this release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Inpixon and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of economic conditions, the impact of COVID-19 on Inpixon’s results of operations and global supply chain constraints, Inpixon’s ability to integrate the products and business from recent acquisitions into its existing business, the performance of management and employees, the regulatory landscape as it relates to privacy regulations and their applicability to Inpixon’s technology, Inpixon’s ability to maintain compliance with Nasdaq’s minimum bid price requirement and other continued listing requirements, the ability to obtain financing, competition, general economic conditions and other factors that are detailed in Inpixon’s periodic and current reports available for review at sec.gov. Furthermore, Inpixon operates in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Inpixon disclaims any intention to, and undertakes no obligation to, update or revise forward-looking statements.

Inpixon Contacts

Media relations and general inquiries:
Inpixon
Email: [email protected]
Web: inpixon.com/contact-us

Investor relations:
Crescendo Communications, LLC
Tel: +1 212-671-1020
Email: [email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inpixon-continues-contract-win-momentum-with-multi-year-smart-office-app-agreement-with-global-social-media-company-to-facilitate-office-reopenings-301326548.html

SOURCE Inpixon

Posted on

Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia


Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease

SEATTLE, July 07, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces it has received regulatory approval from HREC (Human Research Ethics Committee) to open a clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease.

“The COVID-19 pandemic continues to be an urgent health crisis with many regions reporting low vaccination rates combined with new SARS-CoV-2 variants proving more infectious and more deadly,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “If the initial parts of the study are successful we will study the efficacy of our proprietary AT-H201 on moderately ill COVID-19 patients who can be treated via a nebulizer. Our goal in developing nebulized AT-H201 is to improve lung function in patients with active disease, which may reduce the number of patients requiring ventilators and in “long-haul” patients who have residual pulmonary function damage. Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID. The portability of nebulizers, already routinely used for other chronic lung disease, allows for treatment at home.”

The Phase 1/2a placebo-controlled study will enroll a total of 60 healthy participants and moderately-ill hospitalized COVID-19 patients. The study has 4 parts: a single ascending dose part, a multiple ascending dose part, a combination part in healthy individuals and a combination in COVID-19 infected patients and will be conducted with Avance Clinical Pty Ltd., a leading Australian clinical research organization.

AT-H201 is a proprietary combination of two drugs previously approved by the FDA to treat other diseases and by other administration routes. AT-H201 is intended to be inhaled via a nebulizer to improve compromised lung function for moderate to severely ill, hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. In May 2020, we completed in vitro testing of AT-H201 which showed that the components of AT-H201 inhibit SARS-CoV-2 infectivity of VERO cells, which is a standard cell type being used to study infectivity of the coronavirus. The AT-H201 components were found to be at least four times more potent than Remdesivir and at least 20 times more potent than Hydroxychloroquine. Potency was measured by microscopic examination of the cytopathic effect caused by SARS-CoV-2 in VERO cells.

The Phase 1/2a study in Australia and other clinical studies must be successfully completed and regulatory approvals must be obtained before AT-H201 may be commercialized. No assurance can be given than studies will be successful or that regulatory approvals will be obtained.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

Forward-Looking Statements Disclaimer Statement

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:

Atossa Therapeutics, Inc.
Kyle Guse, CFO and General Counsel
Office: (866) 893-4927
[email protected]

Investor Relations Contact:

Core IR
Office: (516) 222-2560
[email protected]



Posted on

Liberty Latin America Releases Inaugural ESG Report

Liberty Latin America Releases Inaugural ESG Report

DENVER, Colorado–(BUSINESS WIRE)–Liberty Latin America Ltd. (“Liberty Latin America” or the “Company”) (NASDAQ: LILA and LILAK, OTC Link: LILAB) today released its inaugural ESG report outlining the Company’s commitment to environment, social, and governance (“ESG”) practices across its operations in Latin America and the Caribbean. The ESG report covers metrics for 2020 and is available on the Company’s website here.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005571/en/

Balan Nair, CEO of Liberty Latin America, said, “On behalf of all our employees at Liberty Latin America, I am proud to present our first ESG report. From the beginning, we have been focused on delivering the best communications products and services to our customers in a way that limits our impact on the environment, uses our reach to bring the digital world to remote and underserved areas, and adheres to high ethical standards. The release of our ESG report is the next step in demonstrating our ongoing commitment to sustainable business practices, positively impacting local communities, and ensuring we do business the right way. This report is just the start, and we look forward to measuring and sharing our ESG journey for years to come.”

The inaugural report was prepared in accordance with the Sustainability Accounting Standards Board (“SASB”) for the Telecommunications Services industry with data through December 31, 2020.

ABOUT LIBERTY LATIN AMERICA

Liberty Latin America is a leading communications company operating in over 20 countries across Latin America and the Caribbean under the consumer brands VTR, Flow, Liberty, Más Móvil, BTC, UTS and Cabletica. The communications and entertainment services that we offer to our residential and business customers in the region include digital video, broadband internet, telephony and mobile services. Our business products and services include enterprise-grade connectivity, data center, hosting and managed solutions, as well as information technology solutions with customers ranging from small and medium enterprises to international companies and governmental agencies. In addition, Liberty Latin America operates a sub-sea and terrestrial fiber optic cable network that connects over 40 markets in the region.

Liberty Latin America has three separate classes of common shares, which are traded on the NASDAQ Global Select Market under the symbols “LILA” (Class A) and “LILAK” (Class C), and on the OTC link under the symbol “LILAB” (Class B).

For more information, please visit www.lla.com,

Investor Relations:

Kunal Patel

[email protected]

Media Relations:

Claudia Restrepo

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Environment Mobile/Wireless Technology Public Relations/Investor Relations Communications Telecommunications Philanthropy Networks Fund Raising Foundation

MEDIA:

Logo
Logo
Photo
Photo
Liberty Puerto Rico (Photo: Business Wire)
Photo
Photo
Photo
Photo
Cable & Wireless Trinidad (Photo: Business Wire)
Photo
Photo
Cable & Wireless British Virgin Islands (Photo: Business Wire)